Overview
- Sionna said it will stop developing SION-719 after a mid‑stage add‑on trial failed to produce a meaningful drop in sweat chloride, a standard measure of cystic fibrosis treatment effect.
- The 14‑day study tested SION-719 in 15 adults already taking Vertex’s Trikafta and found no significant change in sweat chloride despite the drug being generally well tolerated.
- The company said variability in individual test results and differing Trikafta levels among participants may have influenced the outcome and it is reviewing the full data set before deciding next moves.
- News of the trial miss sent Sionna shares into a steep premarket selloff of roughly 92%, underscoring how quickly small biotech stocks can move on clinical setbacks.
- Separately, Sionna reported that an early study of a two‑drug CF candidate (SION-451 plus SION-2222) met initial safety and drug‑exposure goals and is under internal review for possible advancement.